SCHEMBL1676659

SCHEMBL1676659

COC(=O)c1cccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2/C=C/c2ccc(Br)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.43
YTHDC1 Q96MU7 1/20 0.42
MAPT P10636 3/20 0.42
POLB P06746 1/20 0.42
IDO1 P14902 1/20 0.41
CD74 P04233 1/20 0.40
MIF P14174 1/20 0.40
TBXA2R P21731 1/20 0.40
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
THRB P10828 1/20 0.37
ALPL P05186 1/20 0.37
ADCY10 Q96PN6 1/20 0.37
USP2 O75604 1/20 0.36
MAPK10 P53779 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
CXCR2 P25025 1/20 0.36
MAPK8 P45983 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676661 1.00 DRD2 (0.43) DRD2YTHDC1MAPTPOLBIDO1
SCHEMBL1482277 0.92 DRD2 (0.49) DRD2YTHDC1MAPTPOLBGABRA2
SCHEMBL1482273 0.92 DRD2 (0.49) DRD2YTHDC1MAPTPOLBGABRA2
SCHEMBL1481438 0.86 CNR1 (0.42) DRD2YTHDC1MAPTPOLBIDO1
SCHEMBL1481436 0.86 CNR1 (0.42) DRD2YTHDC1MAPTPOLBIDO1
SCHEMBL1482394 0.86 DRD2 (0.48) DRD2MAPTPOLBCD74MIF
SCHEMBL1482391 0.86 DRD2 (0.48) DRD2MAPTPOLBCD74MIF
SCHEMBL1482075 0.85 DRD2 (0.38) DRD2MAPTPOLBTBXA2RGABRA2
SCHEMBL1482079 0.85 DRD2 (0.38) DRD2MAPTPOLBTBXA2RGABRA2
SCHEMBL1676522 0.84 MAPT (0.42) DRD2MAPTPOLBGABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE DRD2 4873/4885YTHDC1 4832/4885MAPT 3251/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE DRD2 4873/4885YTHDC1 4832/4885MAPT 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.